Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IDP-023 |
Trade Name | |
Synonyms | IDP 023|IDP023 |
Drug Descriptions |
IDP-023 comprises a preparation of allogeneic g-NK cells, which potentially induces tumor cell lysis and increases antitumor immune response (Journal for ImmunoTherapy of Cancer 2024;12, NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C202601 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + IDP-023 | Aldesleukin IDP-023 | 0 | 1 |
Daratumumab + IDP-023 | Daratumumab IDP-023 | 0 | 1 |
IDP-023 | IDP-023 | 0 | 1 |
IDP-023 + Rituximab | IDP-023 Rituximab | 0 | 1 |